» Articles » PMID: 18202903

Clinical Manifestations and Natural History of Japanese Heterozygous Females with Fabry Disease

Overview
Publisher Wiley
Date 2008 Jan 19
PMID 18202903
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Fabry disease is an X linked lysosomal storage disorder resulting from deficiency of α-galactosidase A activity. Although disease manifestations in heterozygous females with Fabry disease have been considered to be rare and mild, heterozygous patients with severe symptoms have recently been reported. In this study we focused on the clinical characteristics of Japanese females patients with Fabry disease and analysed data from 36 women. Data on clinical manifestations such as acroparaesthesia, hypohidrosis, angiokeratoma, corneal opacities, proteinuria, end-stage renal disease (ESRD), left ventricular hypertrophy (LVH) and cerebral infarction were obtained by questionnaire; these analysed by the Kaplan-Meier method and compared with the data from Japanese male patients. Eighty-six per cent of female patients had at least one clinical sign of Fabry disease. Their most common symptoms were acroparaesthesia and corneal opacities, and diagnosis was most commonly based on family history. The cumulative incidences of angiokeratoma, corneal opacities, proteinuria, ESRD, LVH and cerebral infarction were significantly lower in female than in male patients. However, corneal opacities, proteinuria and LVH developed progressively in female patients as well as in male patients. The incidence of LVH was especially high in older female patients and the cumulative incidence of LVH in women over 68 years of age was 100%. We consider that the term X-linked 'recessive' is inappropriate for Fabry disease because of the high prevalence of its pathognomonic signs in heterozygous female patients. Careful and long-term evaluation of clinical signs is important in heterozygous females patients with Fabry disease.

Citing Articles

Clinical characteristics of female Fabry disease patients with hypertrophic cardiomyopathy with mid-ventricular obstruction.

Inagaki N, Takei Y, Hatano T, Takada Y, Yazaki Y, Kosuge H Mol Genet Metab Rep. 2025; 42:101196.

PMID: 39995634 PMC: 11849635. DOI: 10.1016/j.ymgmr.2025.101196.


Usefulness of Native T1 in Cardiac Magnetic Resonance Imaging and Echocardiographic Strain Parameters for Detecting Early Cardiac Involvement in Fabry Cardiomyopathy.

Nakagawa S, Amano M, Tamai Y, Mizumoto A, Kurashima S, Irie Y Circ Rep. 2024; 6(10):456-464.

PMID: 39391545 PMC: 11464016. DOI: 10.1253/circrep.CR-24-0068.


Cardiac magnetic resonance in Fabry disease.

Lanzillo C, Fedele E, Martino A, Ferrazza A, Fusco A, Silvetti E Eur Heart J Suppl. 2023; 25(Suppl C):C200-C204.

PMID: 37125302 PMC: 10132562. DOI: 10.1093/eurheartjsupp/suad045.


The role of native T1 values on the evaluation of cardiac manifestation in Japanese Fabry disease patients.

Anan I, Sakuma T, Fukuro E, Morimoto S, Nojiri A, Kawai M Mol Genet Metab Rep. 2022; 31:100858.

PMID: 35782602 PMC: 9248233. DOI: 10.1016/j.ymgmr.2022.100858.


High-Risk Screening for Fabry Disease: A Nationwide Study in Japan and Literature Review.

Sawada T, Kido J, Sugawara K, Nakamura K Diagnostics (Basel). 2021; 11(10).

PMID: 34679477 PMC: 8534369. DOI: 10.3390/diagnostics11101779.


References
1.
Guffon N . Clinical presentation in female patients with Fabry disease. J Med Genet. 2003; 40(4):e38. PMC: 1735431. DOI: 10.1136/jmg.40.4.e38. View

2.
Macdermot K, Holmes A, Miners A . Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet. 2001; 38(11):769-75. PMC: 1734754. DOI: 10.1136/jmg.38.11.769. View

3.
Kampmann C, Baehner F, Whybra C, Martin C, Wiethoff C, Ries M . Cardiac manifestations of Anderson-Fabry disease in heterozygous females. J Am Coll Cardiol. 2002; 40(9):1668-74. DOI: 10.1016/s0735-1097(02)02380-x. View

4.
Linthorst G, Hollak C, Donker-Koopman W, Strijland A, Aerts J . Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta. Kidney Int. 2004; 66(4):1589-95. DOI: 10.1111/j.1523-1755.2004.00924.x. View

5.
Meikle P, Hopwood J, Clague A, Carey W . Prevalence of lysosomal storage disorders. JAMA. 1999; 281(3):249-54. DOI: 10.1001/jama.281.3.249. View